IL161417A0 - Affinity enhancement agents - Google Patents

Affinity enhancement agents

Info

Publication number
IL161417A0
IL161417A0 IL16141702A IL16141702A IL161417A0 IL 161417 A0 IL161417 A0 IL 161417A0 IL 16141702 A IL16141702 A IL 16141702A IL 16141702 A IL16141702 A IL 16141702A IL 161417 A0 IL161417 A0 IL 161417A0
Authority
IL
Israel
Prior art keywords
enhancement agents
affinity enhancement
affinity
agents
enhancement
Prior art date
Application number
IL16141702A
Other languages
English (en)
Original Assignee
Immunomedics Inc
Ibc Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunomedics Inc, Ibc Pharmaceuticals filed Critical Immunomedics Inc
Publication of IL161417A0 publication Critical patent/IL161417A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
IL16141702A 2001-10-15 2002-10-15 Affinity enhancement agents IL161417A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32883501P 2001-10-15 2001-10-15
US34188101P 2001-12-21 2001-12-21
PCT/US2002/032717 WO2003033653A2 (en) 2001-10-15 2002-10-15 Affinity enhancement agents

Publications (1)

Publication Number Publication Date
IL161417A0 true IL161417A0 (en) 2004-09-27

Family

ID=26986533

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16141702A IL161417A0 (en) 2001-10-15 2002-10-15 Affinity enhancement agents

Country Status (13)

Country Link
US (1) US20030113333A1 (de)
EP (1) EP1444267B1 (de)
JP (1) JP4443923B2 (de)
KR (1) KR101027889B1 (de)
CN (1) CN1604910A (de)
AU (1) AU2002335808B2 (de)
BR (1) BR0213284A (de)
CA (1) CA2463616C (de)
IL (1) IL161417A0 (de)
MX (1) MXPA04003533A (de)
PL (1) PL374426A1 (de)
RU (1) RU2004114878A (de)
WO (1) WO2003033653A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6962702B2 (en) * 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
US6346454B1 (en) * 1999-01-12 2002-02-12 Agere Systems Guardian Corp. Method of making dual damascene interconnect structure and metal electrode capacitor
AU2003209446B2 (en) * 2002-03-01 2008-09-25 Immunomedics, Inc. Bispecific antibody point mutations for enhancing rate of clearance
US20050003403A1 (en) * 2003-04-22 2005-01-06 Rossi Edmund A. Polyvalent protein complex
AU2004255216B2 (en) * 2003-07-01 2010-08-19 Immunomedics, Inc. Multivalent carriers of bi-specific antibodies
AU2006218454B2 (en) 2005-03-03 2011-11-17 Immunomedics, Inc. Humanized L243 antibodies
AU2009239491B2 (en) 2008-04-21 2014-07-17 Lawrence Livermore National Security, Llc Selective high-affinity polydentate ligands and methods of making such
CN102481367B (zh) * 2009-07-06 2015-04-29 弗·哈夫曼-拉罗切有限公司 结合地高辛配基的双特异性抗体
US9264453B2 (en) 2013-11-08 2016-02-16 At&T Mobility Ii Llc Front end processor for short message service centers
WO2024184171A1 (en) * 2023-03-03 2024-09-12 Oncoone Research & Development Gmbh Improved bispecific anti-tumor antigen/anti-hsg antibodies for pre-targeting of hyperproliferative disorders

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US6121424A (en) * 1991-11-25 2000-09-19 Enzon, Inc. Multivalent antigen-binding proteins
FR2604092B1 (fr) 1986-09-19 1990-04-13 Immunotech Sa Immunoreactifs destines a cibler les cellules animales pour leur visualisation ou leur destruction in vivo
US5132405A (en) * 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) * 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US6096289A (en) * 1992-05-06 2000-08-01 Immunomedics, Inc. Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy
EP1550729B1 (de) * 1992-09-25 2009-05-27 Avipep Pty Limited Zielmoleküle-bindende Polypeptide bestehend aus einer IG-artigen VL Domäne die an eine IG-artige VH Domäne gebunden ist
WO1994013804A1 (en) 1992-12-04 1994-06-23 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US5874540A (en) * 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
US5989830A (en) * 1995-10-16 1999-11-23 Unilever Patent Holdings Bv Bifunctional or bivalent antibody fragment analogue
DE69729283T2 (de) * 1996-03-20 2005-05-25 Immunomedics, Inc. GLYKOSYLIERTE IgG ANTIKÖRPER
ES2225961T3 (es) * 1996-04-04 2005-03-16 Unilever N.V. Proteina de union a antigeno multivalente y multiespecifica.
US6962702B2 (en) * 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
AU760854B2 (en) * 1998-06-22 2003-05-22 Immunomedics Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
PL372144A1 (en) * 2001-12-26 2005-07-11 Immunomedics, Inc. Methods of generating multispecific, multivalent agents from v sb h /sb and v sb l /sb domains

Also Published As

Publication number Publication date
MXPA04003533A (es) 2005-06-20
WO2003033653A2 (en) 2003-04-24
US20030113333A1 (en) 2003-06-19
BR0213284A (pt) 2006-05-23
PL374426A1 (en) 2005-10-17
KR20050036873A (ko) 2005-04-20
KR101027889B1 (ko) 2011-04-07
EP1444267A2 (de) 2004-08-11
JP2005518344A (ja) 2005-06-23
WO2003033653A3 (en) 2003-11-13
RU2004114878A (ru) 2005-04-20
CA2463616C (en) 2011-07-12
WO2003033653B1 (en) 2004-02-12
AU2002335808B2 (en) 2009-08-27
CN1604910A (zh) 2005-04-06
CA2463616A1 (en) 2003-04-24
JP4443923B2 (ja) 2010-03-31
EP1444267A4 (de) 2009-12-02
EP1444267B1 (de) 2016-08-10

Similar Documents

Publication Publication Date Title
HK1066462A1 (en) Visual function improving agents
EP1293415A4 (de) Verstärkungsteil für kraftfahrzeugen
GB0118662D0 (en) Binding agents
HUP0401534A3 (en) Modified factor ix
DE60210581D1 (en) Substituierte carbostyrilderivate als 5-ht1a-subtyp agonisten
IL157845A0 (en) Anti-epileptogenic agents
IL161417A0 (en) Affinity enhancement agents
IL160539A0 (en) Anti-influenzal agents
AU2002346040A8 (en) Visibility enhancement composition
TWI318229B (en) Dyes having adapted affinity
EP1364646A4 (de) Fenofibrat enthaltende zusammensetzung
GB0105545D0 (en) Boardless iron
AU2002348913A1 (en) Cool-zone iron
GB0122162D0 (en) Agent
GB0106987D0 (en) Immunotherapeuitic agent
DE60236449D1 (en) Neue alpha-oxidierte carbonsäure-phenethylamid-derivate
GB2374899B (en) Stays
GB0100929D0 (en) Control agents
DE60133138D1 (en) (-)-olivil als antioxidationsmittel
GB0129526D0 (en) Magneto-microchannel affinity assays
GB0111831D0 (en) Former
AU147746S (en) Iron
AU147747S (en) Iron
GB0103519D0 (en) Muscarinic agents
GB0123260D0 (en) Binding agents